The case for & against
Bull & Bear analysis
Bullish
Encompass Health Corporation (NYSE: EHC) operates as a leading provider in the integrated post-acute healthcare space, particularly specializing in inpatient rehabilitation services. With a robust network of 169 hospitals and home health locations, the company is strategically positioned to capitalize on the growing demand driven by an aging U.S. population, particularly for rehabilitation to address complex medical conditions such as strokes and neurological disorders. Encompass Health is focused on delivering quality rehabilitation solutions while executing expansion plans to meet increasing market demands.
Bull says
- ↑12% YoY revenue growth to $1.46B and 14.9% adjusted EBITDA rise.
- ↑2025 free cash flow guidance $705M–$795M; Q1 share repurchases of $71.6M support returns.
- ↑Plans to open seven new hospitals (340 beds) in 2026 amid 3% CAGR in 65+ population.
- ↑Raised 2025 net operating revenue guidance to $5.88B–$5.98B, reflecting regulatory navigation confidence.
- ↑Maintained 84% community discharge rate, driving competitive advantage in patient outcomes.
- ↑DCF analysis indicates ~37% undervaluation; strong profitability and earnings yield factors.
Bear says
- ↓Uncertain Medicare policy changes could lower reimbursements and compress margins.
- ↓Elevated staffing and medical group expenses risk further margin erosion.
- ↓Closure of two units trimmed same-store discharge growth by 85bps.
- ↓Net leverage at 1.9x raises balance sheet pressure if growth disappoints.
- ↓Intensifying competition from SNFs, Select Medical, HCA could erode market share.
- ↓Concentration on CMS reimbursements exposes single-point risk to policy shifts.
Investment themes with EHC
Health Care Providers↓ -0.61%
UNH · CVS · HCA
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-02-2026neutral
Transcript signals
Bull points
- Q1 revenue increased 9% to 1.59 billion, and adjusted EBITDA increased 11.2% to 348.8 million.
- Net revenue per discharge growth benefited both from patient mix and a favorable year-over-year comparison in the annual Medicare SSI adjustment.
- We continue to generate significant free cash flow. Q1 adjusted free cash flow was 194 million.
Bear points
- Bad debt expense increased 20 basis points to 2.2%, primarily as a result of writing off claims from 2013 associated with a legacy audit appeal.
- occupancy has become a bit of a constraint in certain markets.
- The higher acuity dynamic of the MA patient, I don't necessarily view it as a positive. You know, it's great from a revenue perspective, but what that signals to me is there's a lot of other patients that should be coming to us that just aren't given the opportunity to do so.
Read full transcript analysis ›